February 1, 2021 5:02pm

Be ready, you never lose money by selling into highs – earnings’ LPS (loss-per-share) season is on its way

Pre-open indication results: 5 HITs and 5 MISS

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting! Numbers based facts speak better then opinion as I see answers in numbers

Sector earnings LPS (loss-per-share) season is about to begin? 

The Dow closed UP +229.29 points (+0.76%); the S&P closed UP +59.62 points (+1.61%) while the Nasdaq closed UP +332.70 points (+2.55%)



Indexes jumped on Monday, the first session of February, as “our” universe of RegMed/Stem/Cell and Gene therapy equities shook-off concerns about a speculative trading that had driven the market’s worst weekly sell-off since October.


RegMed Investors’ (RMi) pre-open: “a sign of returning support and a rebound?” … https://www.regmedinvestors.com/articles/11747


Pre-open indication results: 5 HITs <SELL: Bellicum Pharmaceuticals (BLCM -$0.42), Ionis Pharmaceuticals (IONS -$1.10); BUY: bluebird bio (BLUE +$1.19), Homology Medicine (FIXX +$0.30), Pluristem (PSTI +$0.47)> and 5 MISS < Maintaining SELL: Biostage (BSTG +$0.13 with 1,211 shares traded - market manipulation?), Vericel (VCEL +$3.10), Global Blood Therapeutics (GBT -$0.63), Sage Therapeutics (SAGE +$2.01), Precigen (PGEN -$0.03), >


Data Docket: The ISM PMI, a key gauge of manufacturing activity, came in at 58.7, lower than in December and weaker than economists had expected.


Sentiment and COVID-19 infections:

The U.S.’ vaccine distribution plans face another obstacle as a winter storm is dumping one to two feet of snow from Pennsylvania into New England through Tuesday. < National Weather Service>

Infection cases <Million>: never to forget …

  • Monday 26.18 M cases,
  • Monday’s death rate totaled 441,367 <Johns Hopkins University>


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions 

  • Monday opened positive at 27/7 and 1 flat, stayed positive at the mid-day to 27/7 and 1 flat, closing positive at 22/11, 1 flat and 1 acquired;
  • Friday opened positive at 26/8 and 1 flat, stayed positive at the mid-day to 9/24 and 2 flats, closing negative at 12/22 and 1 acquired;


Key metrics:

  • Sector volume was LOW with 2 of the 22-upside having higher than the 3-month average volume with the increased volume of 2 of 11-downside having higher than the 3-month average volume;
  • Monday’s percentage (%) of the22 -upside were +0.16% (ADVM) to +26.10% (ATHX) while the 11-downside ranges from -0.01% (CRSP) to -9.03% (BLCM);


There are clear winners — and losers — heading into the 2nd  month of 2021.

Jumping with share pricing momentum:

  • Ultragenyx (RARE), Fate Therapeutics (FATE), Regenxbio (RGNX), Vericel (VCEL), BioLife Solutions (BLFS) to name 5 of the 22 inclining of the 35 covered

Hammered in today’s market:

  • Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Global Blood Therapeutics (GBT), Bellicum Pharmaceuticals (BLCM), Brainstorm Cell Therapeutics (BCLI) to name 5 of the 11 declining of the 35 covered


Monday’s (10 of 22) incliners:

  • Ultragenyx (RARE +$7.04 after Friday’s -$2.01);
  • Vericel (VCEL +$3.10 after Friday’s +$0.17);
  • Fate Therapeutics (FATE +$2.53);
  • Sage Therapeutics (SAGE +$2.01 after Friday’s +$1.38);
  • Regenxbio (RGNX +$1.87);
  • BioLife Solutions (BLFS +$1.67);
  • Editas Medicine (EDIT +$1.54 after Friday’s +$0.22);
  • Intellia Therapeutics (NTLA +$1.53 after Friday’s -$1.35);
  • bluebird bio (BLUE +$1.19);
  • Chinook Therapeutics (KDNY +$1.18);

Monday’s (11 of 11) decliners:

  • Alnylam Pharmaceuticals (ALNY -$1.23 after Friday’s -$4.26);
  • Ionis Pharmaceuticals (IONS -$1.10 after Friday’s -$0.62);
  • Global Blood Therapeutics (GBT -$0.63 after Friday’s +$1.78);
  • Bellicum Pharmaceuticals (BLCM -$0.42 after Friday’s +$0.81);
  • Brainstorm Cell Therapeutics (BCLI -$0.33);
  • Voyager therapeutics (VYGR -$0.05);
  • MiMedx (MDXG -$0.05 after Friday’s +$0.57);
  • Caladrius BioSciences (CLBS -$0.04 after Friday’s +$0.08);
  • Solid Biosciences (SLDB -$0.03 after Friday’s +$0.15);
  • Precigen (PGEN -$0.03 after Friday's +$0.07);
  • CRISPR Therapeutics (CRSP -$0.02 after Friday’s -$1.72);

Closing 1 – ReNeuron (RENE.L) and 1 - Stemline Therapeutics (STML – acquired)



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed up +1.28% and XBI closed up +4.41%
  • Friday, the IBB closed up +0.14% and XBI closed up +0.82%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -2.85 points or -8.61% at 30.24
  • Friday was up +2.88 points or +9.53% at 30.09

Upside volume:

  • Monday: 2 out of the 22-upside had higher than the 3-month average volume;
  • Friday: 2 out of the 12-upside had higher than the 3-month average volume;

Downside volume:

  • Monday: 2 out of the 11-downside had higher than the 3-month average volume;
  • Friday: 3 out of the 22-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Monday’s percentage (%) of the22 -upside were +0.16% (ADVM) to +26.10% (ATHX) while the 11-downside ranges from -0.01% (CRSP) to -9.03% (BLCM);
  • Friday’s percentage (%) of the 12-upside were +0.36% (EDIT) to +21.09% (BLCM) while the 22-downside ranges from -0.25% (AGTC) to-4.20% (BCLI);


February, the 2nd month of Q1 … a visual review identifies the range of sector volatility

Monday (2/1) closed positive with 22 advancers, 11 decliners, 1 flat and 1 acquired


The Bottom Line: The return of volatility has many adjusting their portfolios to account for the risks to short positions.

Concerns over stretched valuations, new coronavirus variants and rising COVID-19 cases are keeping all of us on edge about the market and sector pullbacks in addition to the dramatic increase in volatility in the near-term.

There is STILL a short-term tone in the sector – “our’ universe of RegMed, stem, cell and gene therapy equities.

Let’s NOT forget, it is a new tax year thus, a cut back of some (I say many) gains in the sector before the release of Q4 and FY20 “earnings” i.e., LPS (loss-per-share)!

Forewarned … earnings LPS (loss-per-share) season is coming quickly – my advice, trim and skim!!


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.